SYNTHESIS AND CYTOSTATIC PROPERTIES OF DAUNORUBICIN DERIVATIVES, CONTAINING *N*-PHENYLTHIOUREA OR *N*-ETHYLTHIOUREA MOIETIES IN THE 3'-POSITION

M. N. PREOBRAZHENSKAYA, E. V. BAKINA, L. S. POVAROV, E. I. LAZHKO, L. G. Aleksandrova, J. Balzarini[†] and E. de Clercq[†]

Institute of New Antibiotics of the USSR Academy of Medical Sciences, Moscow 119867, USSR [†]Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium

(Received for publication July 2, 1990)


A series of phenylthiourea and ethylthiourea derivatives of daunorubicin and its congeners was prepared by reaction of the 3'-amino group of the antibiotic with phenylisothiocyanate or ethylisothiocyanate. S-Methylation yielded S-methylisothiouronium salts which when reacted with amines resulted in an intramolecular cyclization with the participation of the neighboring 4'-OH group. The structures and predominant conformations of the thiourea derivatives and daunorubicino(3'-N,4'-O-d)oxazolines were determined by ¹H and ¹³C NMR. Cytostatic activities of the thiourea and oxazoline derivatives were compared with the cytostatic activities of N-methylurea and N-methyl-N-nitrosourea containing daunorubicin and its congeners. Carminomycin derivatives were endowed with the highest cytostatic activity.

In the course of a screening program for novel second generation antitumor anthracycline antibiotics of daunorubicin (1) series, derivatives containing in 3'-position N-methylurea (2) or N-methyl-N-nitrosourea moieties (3) were synthesized¹⁾. In alkaline conditions, 3'-(N-methyl-N-nitrosoaminocarbonyl)daunorubicin (3a) or related compounds produce 3'-N,4'-O-carbonyl derivatives by intramolecular cyclization of intermediate 3-deamino-3'-isocyanato derivatives¹⁾. In this paper we report on the preparation of thiourea-containing derivatives of daunorubicin and its analogs which are susceptible to transformations with neighboring 4'-hydroxy group participation. Also, the structure-cytostatic activity relationship among urea and thiourea derivatives of anthracycline antibiotics was investigated.

Chemistry

Daunorubicin (1a), carminomycin (1b), doxorubicin (1c) and 14-pimeloyloxydaunorubicin (1d)¹⁾, upon interaction with phenylisothiocyanate or ethylisothiocyanate in pyridine afforded the corresponding phenylthiourea ($5a \sim 5d$) or ethylthiourea (6a and 6c) derivatives in $77 \sim 99\%$ yield. Previously, 5a was obtained from 1a and phenylisothiocyanate in chloroform-methanol mixture in a yield of $64\%^{21}$. *S*-Methylisothiouronium salts of these compounds 7a, 7b and 8a were obtained by alkylation with CH₃I in methanol. Usually *S*-alkylisothiouronium salts easily produce guanidines by the action of amines. Compounds 7 and 8 were selected for their transformation to substituted guanidine derivatives (9). Upon interaction with primary amines (methylamine, *n*-pentylamine or tris(hydroxymethyl)aminomethane) 7a, 7b and 8a yielded daunorubicino(3',4'-d)oxazoline derivatives (10a, 10b or 11a), respectively. The formation of a 5-membered cycle is facilitated as in the case of transformations of *N*-methyl-*N*-nitrosoaminocarbonylderivatives of daunorubicin (4)¹⁾.

We could demonstrate by HPLC that storage of S-methylisothiouronium salt 7a during 1-day in



methanol, resulted in the oxazoline derivative 10a; the transformation of 7a to oxazoline 10a in acetonitrile proceeded at room temperature during one month. The interaction of primary amines (methylamine, *n*-pentylamine or tris(hydroxymethyl)aminomethane), with 7a or 8a led in all cases to the same products 10a or 11a, respectively. HPLC analysis of fresh methanolic solution of 7a after addition of methanolic ammonia demonstrated the presence of 7a and 10a. Storage of this solution led to complete transformation of 7a to 10a.

The structures assigned to the thiourea derivatives **5** and **6** and the oxazoline-containing antibiotics **10** and **11** were supported by ¹³C and ¹H NMR. In the Table 1 selected ¹H NMR data for thiourea and oxazoline derivatives are listed. Conformation of the carbohydrate ring in compounds **5** and **6** is similar to that of the parent antibiotics **1** ($_4C^1$). Carbon resonance assignments have been made from single-resonance spectra ¹³C and 2D-¹³C-¹H shift correlated spectroscopy *via* direct and long-range C-H couplings.

S-Methylthiouronium salts of teicoplanin in alkaline conditions gave rise to an intramolecular cyclization with the formation of both oxazoline- and imidazolone derivatives³, but in our case the imidazolone compound 12 was not formed. Significant differences of chemical shifts of C-4' and C-3' carbons (up to 20 ppm) in the cyclization products fit more closely to structures 10a and 11a, and exclude the possibility of imidazolone 12 formation.

The cyclic structure of 10a and 11a was confirmed by selective double resonance ¹³C-¹H. Coupling constant J=3 Hz between carbon C-NHPh and 4'-H demonstrated that spin coupling proceeds through 3 bonds, but not 4 bonds, as it would have been if the oxazoline structure was not closed.


The structures 10 and 11 are possibly in tautomeric equilibria with the structure 13 (10(11) \approx 13). Comparison of chemical shifts of carbon atoms of the phenyl ring with the data for corresponding model compounds, containing this fragment in amino or imino-forms^{4,5}, indicates that the amino-tautomer is predominant for 10a in CDCl₃ and for 11a in CDCl₃-CD₃OD solution.

¹H NMR data demonstrated that incorporation of C-3' and C-4' atoms into a 5-membered cycle leads to change of conformation ${}_{4}C^{1}$ (14) of the daunosamine cycle (Table 1). Coupling constants $J_{2'_{b,3'}} = 2.3$ Hz and $J_{2'_{a,3'}} = 3.8$ Hz indicate the absence of trans-diaxial coupling of these protons, which means that the 3'-H proton is equatorial. The large $J_{3',4'}=9.6$ Hz is possibly connected with a decrease of dihedral angle 3'-H~4'-H due to cyclization. Similar findings have been described for another

	Chemical shifts								Coupling constants						
Compound-	1'-H	2'-H _a	2'-H _b	3'-H	4'-H	5'-H	5'-CH3	l',2'b	1′,2′a	2'a,2'b	2'b,3'	2'a,3'	3′,4′	4′,5′	
5a	5.49	2.06	1.68	4.73	3.38	4.25	1.27	3.9	<1	13.3	13.3	5.2	2.7	0.7	
5b	5.45	2.13	1.69	4.76	3.77	4.26	1.28	4.1	<1	13.0	13.0	5.1		<1	
5c	5.50	2.06	1.67	4.73	3.77	4.18	1.27	3.9	0.9	13.3	13.3	5.0	2.6	0.9	
5dª	5.37	1.84	1.64	4.50	3.58	4.09	1.16	3.5	<1	13.4		5.2		<1	
6a	5.49	2.02	1.78	4.65	3.78	4.24	1.29	3.8	<1	13.2	13.2	4.8	2.7	<1	
6c ^a	5.44	1.85	1.76	4.46	3.65	4.12	1.23	3.9	<1	13.2	13.2	5.0		<1	
10a	5.51	1.68	2.48	4.49	4.52	4.07	1.36	5.9	8.3	15.3	2.3	3.8	9.6	1.2	
10b	5.49	1.69	2.50	4.50	4.50	4.05	1.37	5.9	8.0						
11a	5.56	1.69	2.52	4.52	4.95	4.17	1.38	6.3	7.8	16.0	2.2	3.5	9.5	1.5	


Table 1. ¹H NMR assignments of signals of sugar moieties of compounds 5a~5d, 6a, 6c, 10a, 10b and 11a in CDCl₃ (*dopm*) with CHCl₃ internal reference (7.25) and spin coupling constants (Hz).

Small amounts of CD₃OD were added.





15a





16

3',4'-cyclo derivative of daunorubicin $(15)^{6}$ as well as for 3'-N,4'-O-carbonyl derivatives of these antibiotics $(4)^{1}$. It suggests that cyclic derivatives of this type are in distorted conformation ${}_{1}C^{4}$ (16) or in twist-boat conformation. It is interesting to note that the coupling constants of the sugar protons in the compounds 10, 11, 12 and 15 are rather close to the coupling constants of the sugar protons of the doxorubicin base in CD₃COCD₃ solution⁷). It means that the relative distribution of the various forms of these cyclic compounds can be similar to that of the natural antibiotics.


In the IR spectra of the compounds **10a**, **10b** and **11a** neither the frequency of an imidazolone CO group at 1705 cm^{-1} nor the absorption at 1735 cm^{-1} characteristic for urea¹⁾ is present. An absorption peak at 1680 cm^{-1} demonstrated the presence of C=N group in these compounds.

Akin to the oxazolinone compounds 4^{1} , the derivatives 10a, 10b and 11a demonstrated $[\alpha]_D$ values that were very different from the starting compounds 1, 5 and 6 (Table 2).

Com- pound		MP (°C)	[α] _D (°)	Calcd					Found					IR (KBr)
				С	н	Ν	S	Molecular formula	C	Н	N	S	Rf	cm^{-1}
5a	96.4	162	+ 82ª	60.00	5.33	4.11	4.70	$C_{34}H_{34}N_2SO_{10} \cdot H_2O$	60.37	5.35	4.00	4.85	0.51	1530, 1500, 1230
5b	80.5	160	+146°	59.45	5.14	4.20	4.81	$C_{33}H_{32}N_2SO_{10} \cdot H_2O$	59.57	5.04	4.04	4.83	0.47	1535, 1500, 1246
5c	98.7	128	+102°	57.86	5.28			$C_{34}H_{34}N_2SO_{11} \cdot l\frac{1}{2}H_2O$	57.94	5.34			0.45	1540, 1500, 1240
5d	76.6	144	+145 ^b	57.47	5.65	3.27		$C_{41}H_{44}N_2SO_{14} \cdot 2H_2O$	57.43	5.41	3.39		0.44	$1548 \sim 1530$, 1505, 1240
6a	92.1	164	+269ª	57.77	5.66	4.49		$C_{30}H_{34}N_2SO_{10}\cdot \frac{1}{2}H_2O$	57.74	5.74	4.22		0.50	$1550 \sim 1540$, 1230
6c	92.1	188	+207ª	53.33	5.82	4.14		$C_{30}H_{34}N_2SO_{11}{\cdot}2_2^1H_2O$	53.14	5.72	3.92		0.34	1560~1550, 1249
10a	63.6	157	-260ª			4.45		$C_{34}H_{33}N_2O_{10}$			4.27		0.55	
10b	58.4	158	-265 ^b										0.54	
11a	52.2	166	— 66ª	58.43	5.56	4.54		$C_{30}H_{32}N_2O_{10}\cdot 2H_2O$	58.10	5.63	4.29		0.24	1680, 1230

Table 2. Preparation and physical properties of compounds 5a~5d, 6a, 6c, 10a, 10b and 11a.

^a (c 0.05, CHCl₃). ^b (c 0.01, CHCl₃). ^c (c 0.05, CHCl₃-CH₃OH, 9:1).



196

THE JOURNAL OF ANTIBIOTICS

We attempted to obtain a 3'-guanidine-containing derivative of daunorubicin (9) by the interaction of the antibiotic 1a (as base) with S-methylisothiouronium methylsulfate in the presence of alkali. 7-Deoxy-7-methylthiodaunomycinone (18) was isolated by TLC in a yield of 14%. It suggests that MeSH produced from S-methylisothiouronium salt reduced the anthraquinone nucleus of 1a with the formation of the leuco derivatives 17; cleavage of the glycosyl bond and attachment of a second molecule of methylmercaptane with following oxidation afforded 18 in a reaction sequence similar to that proposed for the interaction of 1a with Na₂S₂O₄⁸⁾.

Cytostatic Activity

The inhibitory activity of the thiourea (5 and 6) and oxazoline (10) derivatives on the proliferation of murine leukemia cells L1210, human B-lymphoblast cells (Raji) and T-lymphoblast cells (Molt-4F) were compared with the inhibitory activity of the N-methylurea (2), N-methyl-N-nitrosourea (3) and oxazolone (4) derivatives described previously¹⁾. The IC₅₀ of the test compounds are presented in Table 3. The most potent cytostatic agent was carminomycin 1b; all derivatives of 1b (*i.e.*, compounds 2g, 3b and 4b) were ten to one hundred times more active than the corresponding derivatives of daunorubicin (1a) (*i.e.*, compounds 2a, 2f, 3a, 4a, 5a, 6a and 10a). Doxorubicin (1c) and some of its derivatives 2c and 5c were considerably less inhibitory to tumor cell proliferation than daunorubicin 1a and its derivatives 2a and

	Inhibitio	n of tumor cell pro	Inhibition of HIV-1 replication					
Compound	L1210	Raji	Molt-4F	in MT-4 cells				
=		IC ₅₀ ^а (µм)	$CC_{50}{}^{b}(\mu M)$	EC ₅₀ ^с (µм)				
1a*	0.04	0.017	0.044					
1b*	0.005	0.002	0.005					
1c*	0.367	0.043	0.056					
2a	0.556	0.488	0.577					
2c	6.217	4.017	6.25					
2d	3.98	1.858	4.362					
2e	2.99	1.011	3.805					
2f*	1.76	1.26	1.71					
2g*	0.037	0.018	0.041					
3a	1.631	0.538	0.509					
3b	0.045	0.041	0.047					
3c	0.636	0.180	0.437					
4a	1.40	0.733	0.655	3.25	>1.80			
4b	0.077	0.042	0.072	0.313	> 0.19			
5a	0.702	0.507	0.737					
5c	1.127	0.432	0.748					
5d	0.526	0.361	0.755					
6a	0.293	0.084	0.280	0.379	>0.16			
6c	0.347	0.049	0.284	0.248	>0.16			
10a	1.65	0.392	0.838	0.386	>0.16			

Table 3. Inhibitory effects of urea and thiourea derivatives of daunorubicin and related compounds on the proliferation of murine leukemia L1210, human B-lymphoblast (Raji) and human T-lymphoblast (Molt-4F) cells, and their inhibitory effects on HIV-1-induced cytopathogenicity in T-lymphocyte (MT-4) cells.

^a IC_{50} required to inhibit tumor cell proliferation by 50%.

^b Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%.

^c Effective concentration of compound required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1.

* Asterisks indicate values for the antibiotic hydrochlorides.

5a. Conversion to alkali-soluble depot forms of doxorubicin $(2a \rightarrow 2d, 2e; 5a \rightarrow 5d)$ or acid-soluble depot forms (2g and 2f) did not result in an enhancement of the cytostatic activity. Comparison of 3a with 4a and 3b with 4b indicates that the cytostatic properties of the *N*-methyl-*N*-nitrosourea derivatives are not more pronounced than those of their degradation products which have no alkylating moieties. Only in doxorubicin series the presence of the cytotoxic group 3c led to a 10-fold increase of the cytostatic activity (in comparison with 2c).

As demonstrated previously, the structure-activity relationship of daunorubicin derivatives is quite different from that of carminomycin derivatives.

When evaluated on their inhibitory effects on human immunodeficiency virus (HIV), none of the compounds 4a, 4b, 6a, 6c, and 10a showed anti-HIV-1 activity in human T-lymphocyte (MT-4) cells at subtoxic concentrations.

Experimental

Physico-chemical determinations were made on the following instruments: NMR; VXR-400 (Varian, U.S.A), EI-MS; Varian-MAT-112 spectrometer at $210 \sim 230^{\circ}$ C ion source temperature and 70 eV electron energy, samples being introduced by direct insertion, IR spectra in KBr spectrophotometer SP-1100 (Pye Unicam, England), $[\alpha]_{D}$ determination; polarimeter Perkin-Elmer 241.

Analytical HPLC was performed on DuPont (U.S.A.) instrument 8800 equipped with a UV detector at 254 nm and Zorbax C8 (4.6×250 mm, 5μ m) column, flow rate 1 ml/minute at 37°C, mobile phases: (A) acetonitrile and 0.01 M orthophosphoric acid 30:70; (B) acetonitrile and 0.05 M of NaH₂PO₄ (pH 3.2) (30:70). Rt of **5a** 10.4 minutes, Rt of **6a** 7.3 minutes, Rt of **7a** 16.9 minutes, Rt of **8a** 13.8 minutes, Rt of **10a** 18.4 minutes, Rt of **11a** 13.7 minutes (A system), Rt of daunomycinone 5.89 minutes, Rt of **18** 7.44 minutes (B system).

TLC was carried out on Silufol plates (Kavalier, Czechoslovakia) in chloroform - benzene - methanol (10:1:2).

Properties of the compounds are presented in Table 2. The assays for measuring inhibition of tumor cell growth and anti-HIV-1 activity in MT-4 cells were performed as previously described^{9,10}.

Phenylthiourea Derivatives $5a \sim 5d$ and Ethylthiourea Derivatives 6a and 6c

To a solution of the antibiotic $1a \sim 1d$ (2g) in 150 ml of dry pyridine phenylisothiocyanate (2.5 ml) or ethylisothiocyanate (3 ml) was added. The solution was stirred at room temperature for 24 hours (for phenylisothiocyanate) or 48 hours (for ethylisothiocyanate), then evaporated to a minimal volume *in vacuo* and the product ($5a \sim 5d$ or 6a and 6c) was precipitated with ether (200 ml). For analytical purposes the substances were purified by TLC.

S-Methylisothiouronium Salts 7a, 7b and 8a

A solution of thiourea derivatives 5a, 5b or 6a (600 mg) and 0.6 ml of MeI in dry methanol (70 ml) was stirred at room temperature for 2 hours (5a and 5b) or 24 hours (6a). The reaction mixture was filtered, the filtrate was evaporated *in vacuo*, dissolved in chloroform (5 ml) and the product was precipitated by addition of hexane (50 ml), with yields of $70 \sim 85\%$.

Oxazoline Derivatives 10a, 10b and 11a

To a solution of S-methylisothiouronium iodates 7a, 7b or 8a (250 mg) in methanol (20 ml) *n*pentylamine was added and the reaction was left overnight. The precipitate was collected by filtration, washed with methanol, dissolved in chloroform and washed with NaHCO₃ solution and then with water. After evaporation till minimum volume and addition of hexane, the crystalline oxazolines 10a, 10b or 11a were obtained. For analysis the compounds were purified by TLC. Compound 10a was purified by column chromatography (silica gel) upon elution with benzene, benzene-acetone (87:13) and methanol. The methanol fraction was evaporated and the product was obtained after precipitation with ether. ¹³C NMR data for **10a** in CDCl₃: C-1 119.58, C-2 135.50, C-3 118.27, C-4 160.85, C-4a 120.70, C-5 186.54, C-5a 111.11 (or 111.05), C-6 156.33, C-6a 133.93, C-7 69.18, C-8 35.17, C-9 76.83, C-10 33.07, C-10a 134.46, C-11 155.66, C-11a 111.05 (or 111.11), C-12 186.40, C-12a 135.25, C-13 212.32, C-14 24.81, OCH₃ 56.41, C-1' 100.02, C-2' 29.91, C-3' 58.23, C-4' 78.85, C-5' 64.60, C-6' 16.26, C(-NHPh) 157.03; phenyl ring: C *ipso* 139.60; C *oriho* 119.33; C *meta* 129.00; C *para* 122.77 ppm.

¹³C NMR data for **11a** in CDCl₃-CD₃OD: C-1 119.46, C-2 135.53, C-3 118.83, C-4 160.73, C-4a 120.48, C-5 186.68, C-5a 111.13 (or 111.00), C-6 155.80, C-6a 133.66, C-7 68.79, C-8 35.00, C-9 76.62, C-10 32.78, C-10a 134.15, C-11 155.22, C-11a 111.00 (or 111.13), C-12 186.42, C-12a 135.10, C-13 212.70, C-14 24.51, OCH₃ 56.33; C-1' 99.84, C-2' 29.88, C-3' 58.41, C-4' 79.02, C-5' 64.49, C-6' 14.85, C(-NHC₂H₅) 161.04, N-CH 37.25, N-CH₂-CH₃ 14.65 ppm.

7-Deoxy-7-methylthiodaunomycinone (18)

Daunorubicin base was dissolved in water-propanol mixture (1:1). S-Methylisothiouronium methylsulfate (0.4 g) and 10% NaOH (2 ml) were added, and the reaction mixture was heated at 60° C for 2 hours (methylmercaptane smell was detected). The product was extracted with chloroform, the solution was washed with water and evaporated till minimal volume and precipitated with ether. By TLC in A system 0.06 g (14.8%) of compound 18 was isolated.

Anal Calcd for C₂₂H₂₀O₇S: C 61.68, H 4.70. Found: C 61.66, H 4.78.

¹H NMR data (CDCl₃) δ 7.98 (1H, d, $J_{1,2}$ = 7.7 Hz, 1-H), 7.73 (1H, t, 2-H), 7.34 (1H, d, $J_{3,2}$ = 8.4 Hz, 3-H), 4.71 (1H, dd, $J_{7,8b}$ = 3.8 Hz and $J_{7,8a}$ = 7.8 Hz, 7-H), 4.06 (3H, s, OCH₃), 3.20 (1H, d, $J_{a,b}$ = 15.2 Hz, 10-H_b), 3.12 (1H, d, 10-H_a), 2.49 (1H, d, 8-H_b), 2.29 (1H, dd, $J_{a,b}$ = 15.20 Hz, 8-H_a), 2.45 (3H, s, SCH₃), 2.13 (3H, s, 14-H).

Mass spectrum: 428 (87.8%, $C_{22}H_{20}O_7S$), 382 (15.9%, $M-SCH_3+H$), 362 (16.7%, $M-SCH_3-H_2O-H$), 337 (100%, $M-SCH_3-COCH_3-H$), 383 (15.61%, $M-COCH_3-2H$).

Acknowledgments

This research was supported in part by a grant from the Belgium "Nationaal Fonds voor Wetenschappelijk Onderzoek", Project No. 7.0040.90.

References

- POVAROV, L. S.; E. V. BAKINA, E. I. LAZHKO, G. I. ORLOVA, O. S. ZHUKOVA, N. A. OBIDNIAK, N. Y. YURCHENKO, T. Y. GLADKOVA & M. N. PREOBRAZHENSKAYA: Methylurea or methylnitrosourea containing derivatives of antitumor antibiotic daunorubicin. Bioorg. Khim. 16: 559~568, 1990.
- YAMAMOTO, K.; E. M. ACTON & D. W. HENRY: Antitumor activity of some derivatives of daunorubicin at the amino and methyl ketone functions. J. Med. Chem. 15: 872~875, 1972
- TRANI, A.; P. FERRARI, R. PALLANZA & R. CIABATTI: An unexpected intramolecular cyclization of isothiouronium teicoplanins. II. Reaction mechanism and biological activity. J. Antibiotics 42: 1276~1282, 1989
- 4) JACKMAN, L. M. & T. JEN: ¹H and ¹³C Nuclear magnetic resonance studies on the tautomerism, geometrical isomerism, and conformation of some cyclic amidines, guanidines, and related systems. J. Am. Chem. Soc. 97: 2811 ~ 2818, 1975
- 5) NEGREBETSKY, V. V.; T. V. ALESHNIKOVA, A. F. PROKOFIEVA, A. F. GRANOV & N. N. MELNIKOV: Investigation by ¹H and ¹³C NMR methods of tautomerism and isomerism of 2-R-aminopyrrolines and their analogues tetrahydropyridines and adenines. Zh. Obshch. Khim. 57: 1846~1852, 1987
- 6) NAKAJIMA, S.; H. KAWAI, M. SAKAKIBARA, K. TATSUTA, N. OTAKE & H. UMEZAWA: Synthesis of 4'-O-acylanthracyclines. Agric. Biol. Chem. 52: 3191~3192, 1988
- ALLMAN, T. & R. E. LENKINSKI: A conformational analysis of adriamycin based upon its NMR spectrum in various solvents. Can. J. Chem. 65: 2405 ~ 2409, 1987
- BIRD, D. M.; M. BOLDT & T. H. KOCH: Leucodaunomycin, a tautomer of daunomycin hydroquinone. J. Am. Chem. Soc. 111: 1148~1150, 1989
- 9) DE CLERCQ, E.; J. BALZARINI, P. F. TORRENCE, M. P. MERTES, C. L. SCHMIDT, D. SHUGAR, P. G. BARR, A. S. JONES, G. VERHELST & R. T. WALKER: Thymidylate synthetase as target enzyme for the inhibitory activity of 5-substituted 2'-deoxyuridines on mouse leukemia L1210 cell growth. Mol. Pharmacol. 19: 321~330, 1981

VOL. 44 NO. 2

10) BALZARINI, J.; M. BABA, R. PAUWELS, P. HERDEWIJN, S. G. WARD, M. J. ROBINS & E. DE CLERCQ: Potent and selective activity of 3'-azido-2,6-diaminopurine-2',3'-dideoxyriboside, 3'-fluoro-2,6-diaminopurine-2',3'-dideoxyriboside, and 3'-fluoro-2',3'-dideoxyguanosine against human immunodeficiency virus. Mol. Pharmacol. 33: 243~249, 1988